Keros Therapeutics (KROS) Q1 2026 Earnings
Keros Therapeutics reported Q1 2026 revenue of $367.0K (-99.8% YoY), missed analyst consensus of $1.9M by $1.6M. Diluted EPS came in at $-1.21, missed the $-1.02 consensus by $0.19.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Keros Therapeutics's Q1 2026 earnings report.
Keros Therapeutics (KROS) reported Q1 2026 earnings on May 14, 2026 before market open.
Keros Therapeutics reported revenue of $367.0K and diluted EPS of $-1.21 for Q1 2026.
Revenue missed the consensus estimate of $1.9M by $1.6M. EPS missed the consensus estimate of $-1.02 by $0.19.
Compared to the same quarter a year prior, revenue declined 99.8% from $211.2M a year earlier.
You can read the 8-K earnings release (0001664710-26-000029) and the 10-Q periodic report (0001664710-26-000030) directly on SEC EDGAR. The filing index links above go to sec.gov.